Safety and Feasibility of Chimeric Antigen Receptor T Cell Therapy after Allogeneic Hematopoietic Cell Transplantation in Relapsed/ Refractory B Cell Non-Hodgkin’s Lymphoma

Benzer Materyaller

• Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 CAR T-cell therapy
  Yazar:: Imber, Brandon S., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
  Yazar:: Lin, Richard J., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma
  Yazar:: Lin, Richard J., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• NCMP-07. CLINICAL NEUROLOGICAL FEATURES AND ELECTROGRAPHIC PATTERNS OF PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL AT MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC)
  Yazar:: Sequeira, Alexandra, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
  Yazar:: Pennisi, Martina, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)